Suven grants exclusive license to Taro Pharmaceuticals

On March 4, 2014, Suven announced that it has granted an exclusive license, and the right to distribute and market its Malathion Lotion USP 0.5% w/v in USA, Canada and Mexico to Taro Pharmaceuticals.

malathion

Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.

In this regard, Taro will pay Suven a royalty and the arrangement is effective until April 2028, unless otherwise terminated.

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email

X